title: Occult HBV reactivation induced by ibrutinib treatment: a case report.
abstract: Ibrutinib is a small molecule that has been recently developped for the treatment of B cell malignancies. Common side effects are diarrhoea, nausea, fatigue, infections, neutropenia and thrombocytopenia. Here we report the first case of Hepatitis B virus reactivation in a 80 years old chronic lymphocytic leukaemia patient receiving ibrutinib, suggesting that such treatment must be associated with HBV screening.
authors.forename: Patrick
authors.initials: P
authors.lastname: de Jésus Ngoma
authors.forename: Benoît
authors.initials: B
authors.lastname: Kabamba
authors.forename: Geraldine
authors.initials: G
authors.lastname: Dahlqvist
authors.forename: Christine
authors.initials: C
authors.lastname: Sempoux
authors.forename: Nicolas
authors.initials: N
authors.lastname: Lanthier
authors.forename: Tony
authors.initials: T
authors.lastname: Shindano
authors.forename: Eric
authors.initials: E
authors.lastname: Van Den Neste
authors.forename: Yves
authors.initials: Y
authors.lastname: Horsmans
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000369:Aged, 80 and over; D006509:Hepatitis B / Q000209:etiology* / Q000473:pathology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010880:Piperidines; D011720:Pyrazoles / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D014775:Virus Activation
chemical_list: D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine